2CUREX AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.4 SEK | +1.27% |
|
-5.21% | -80.10% |
| Feb. 29 | 2curex AB Elects Grith Hagel as a New Board Member | CI |
| Feb. 22 | 2cureX AB Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2021 | 7.39M 684K | Sales 2022 | 3.37M 312K | Capitalization | 143M 13.27M |
|---|---|---|---|---|---|
| Net income 2021 | -18M -1.67M | Net income 2022 | -29M -2.68M | EV / Sales 2021 | 29.9 x |
| Net cash position 2021 | 72.94M 6.75M | Net cash position 2022 | 44.89M 4.15M | EV / Sales 2022 | 29.3 x |
| P/E ratio 2021 |
-14.6
x | P/E ratio 2022 |
-4.81
x | Employees | 14 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 42.42% |
More Fundamentals
* Assessed data
More news
Latest transcript on 2cureX AB
More press releases
| 1 day | +1.27% | ||
| 1 week | -5.21% | ||
| Current month | +12.99% | ||
| 1 month | -4.76% | ||
| 3 months | -81.90% | ||
| 6 months | -85.71% | ||
| Current year | -80.10% |
1 week
0.36
0.44
1 month
0.300.58
Current year
0.292.79
1 year
0.297.50
3 years
0.2926.50
5 years
0.2931.50
10 years
0.2931.50
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 48 | 21-01-31 | |
Grith Hagel
FOU | Founder | 65 | 05-12-31 |
Ole Thastrup
FOU | Founder | 71 | 05-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ole Thastrup
FOU | Founder | 71 | 05-12-31 |
| Chairman | - | Nov. 13 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-23 | 0.4 | +1.27% | 25 491 |
| 24-04-22 | 0.395 | -1.25% | 19,509 |
| 24-04-19 | 0.4 | -5.66% | 1,854 |
| 24-04-18 | 0.424 | -3.42% | 2,891 |
| 24-04-17 | 0.439 | +4.03% | 8,460 |
Delayed Quote Nasdaq Stockholm, April 23, 2024 at 11:23 am EDT
More quotes
2cureX AB is a Sweden-based company engaged in the biotechnology sector. The Company focuses on the research and development of diagnostic substances to select treatment for cancer patients. The Company's product candidate, IndiTreat - CRC, aims at optimizing medical treatment for the colorectal cancer patients. Through IndiTreat - CRC, healthcare professionals collect a tumor sample from patients to create a number of three-dimensional micro tumors in order to test available chemotherapies and experimental treatments. The Company's product pipeline includes also IndiTreat - OVA, targeting ovarian cancer treatment, and IndiTreat - KDN, focusing on kidney cancer treatment. It operates through 2cureX A/S.
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -80.10% | 637K | |
| -13.58% | 11.33B | |
| +45.63% | 3.16B | |
| -35.38% | 2.14B | |
| -18.27% | 2.04B | |
| -27.26% | 1.49B | |
| +18.17% | 975M | |
| -3.49% | 731M | |
| -30.25% | 423M | |
| +26.64% | 371M |
- Stock Market
- Equities
- 2CUREX Stock
